A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute noncardioembolic ischemic stroke or high-risk TIA

  • Cloud, Geoffrey (Primary Chief Investigator (PCI))
  • Murphy, Lily (Project Manager)

Project: Research

Project Details

Project Description

Effective start/end date13/02/2330/12/25


  • clinical trial
  • ischemic stroke
  • TIA
  • oral inhibitor